Colgate-Palmolive Company (CL) Stock: Price, Forecast & Analyst Target
Colgate-Palmolive Company (CL) — MoonshotScore 93/100 (Exceptional band), calculated Nov 18, 2026. Price $98.85 (-0.76%), as of the Nov 18, 2026 trading session; market cap $78.6B. Expected results Jan 29, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Colgate-Palmolive Company · CL · NYSE · Consumer Defensive · Household & Personal Products
Research dated 2026-09-12: Colgate-Palmolive sells repeat-purchase oral, personal and home-care products alongside Hill's pet nutrition through retail, dental and veterinary channels. The case hinges on whether steady sales expansion can absorb higher input costs, tariffs and planned brand spending while restoring the conversion of revenue into operating profit.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Colgate-Palmolive Company (CL)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Elite quality and a strong balance sheet, but an expensive valuation; the market is already moving on it. Business Quality: Elite; Financial Safety: Sound; Valuation: Rich; Growth Durability: Growing; Momentum: Rising.
Price relative to book value is the main valuation drag relative to sector peers.
- quarterly revenue $5.13B (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 8 of the last 8 reports
- expected results Jan 29, 2027
Holding back: a rich price
Helping: business quality, balance-sheet strength, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 87 | Exceptional | |
| 89 | Exceptional | |
| 89 | Exceptional | |
| 89 | Exceptional | |
| 93 | Exceptional | |
| 93 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $98.85 | |
| Change on the day | -0.76% | |
| 52-week range | $75.96–$101.81 | |
| Market capitalisation | $78.6B | — |
| Price / earnings (trailing) | 38.70 | |
| Shares traded on the day | 6.07M | |
| Beta (volatility vs the S&P 500) | 0.31 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Colgate-Palmolive Company (CL): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Colgate-Palmolive Company (CL), and what does it report?
Short answer · as of
Colgate-Palmolive is much more than a toothpaste and soap company.
Research dated 2026-09-12.
Its main business spans oral care, personal care and household products, while Hill's sells everyday and therapeutic nutrition for dogs and cats; professional oral-health products add dentists to a distribution network otherwise built around retailers, wholesalers, veterinary clinics and online platforms.
Reported revenue separates Oral, Personal and Home Care from Pet Nutrition. The consumer-care group remains the larger contributor, but the pet business gives the company exposure to animal health needs and veterinary distribution rather than only household shopping patterns.
What do the latest results show for Colgate-Palmolive Company (CL)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $5.13B.
Research dated 2026-09-12.
Sales advanced again in the latest period, extending an upward annual trajectory. Gross profit also increased, but operating profit pulled back alongside higher selling, general and administrative expense, so the latest top-line gain did not fully reach operating earnings. Net income improved from the preceding period after the unusual loss recorded around the annual close.
Reported earnings have repeatedly exceeded expectations, while revenue has beaten estimates in nearly every recent release. Management attributes the prospective improvement path to new-product execution, closing promotional gaps, greater advertising support and a broader productivity program; those are stated priorities, not yet proof that profit conversion has recovered.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $5.37B Oct 30, 2026
- Latest report · revenue estimate
- $5.34B Oct 30, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 30, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 30, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 30, 2026 | $5.37B | $5.34B | $0.9700 | $0.9260 |
| Jul 31, 2026 | $5.36B | $5.36B | $0.9900 | $0.9470 |
| May 1, 2026 | $5.32B | $5.22B | $0.9700 | $0.9430 |
| Jan 30, 2026 | $5.23B | $5.12B | $0.9500 | $0.9120 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $5.13B | $735M | $0.91 (diluted) |
| Q4 FY2025 | $5.23B | -$37M | -$0.05 (diluted) |
| Q1 FY2026 | $5.32B | $646M | $0.80 (diluted) |
| Q2 FY2026 | $5.36B | $693M | $0.86 (diluted) |
What are the financial strengths and risks for Colgate-Palmolive Company (CL)?
Short answer
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Operating cash flow has exceeded capital spending throughout the reported series, leaving meaningful internally generated funds after investment in the business. Cash has remained within a relatively narrow range and finished only modestly below its opening level, which points to stability rather than a persistent operating drain.
Debt materially exceeds cash and short-term investments. Near-term liquidity appears adequate but not abundant, making sustained cash generation more important than the cash balance alone; strong distress and financial-quality screens provide a counterweight, but they do not remove refinancing or execution risk.
Higher raw-material costs and tariffs could pressure gross profit just as management increases advertising. That combination would hurt if brand support fails to produce enough sales or pricing benefit, especially because annual revenue growth has recently coexisted with uneven net income.
What should you watch next at Colgate-Palmolive Company (CL)?
Short answer · as of
The next earnings report is expected on Jan 29, 2027.
Research dated 2026-09-12.
The next release should be judged on the link between sales, gross profit and operating profit rather than revenue alone. Management expects greater raw-material and tariff pressure later in the year while stepping up advertising and addressing promotion gaps and new-product execution. Continued sales progress with stable gross profitability and firmer operating profit would support that plan; weakening gross profit as spending rises would challenge it.
Cost actions also deserve attention. Recent company reporting flagged costs associated with exit or disposal activities, while management tied its longer-term strategy to productivity and organizational structure. The useful test is whether those actions improve profit conversion rather than merely shift expenses.
Analyst forecasts assume revenue and earnings continue rising across the forecast horizon. Upcoming results therefore need to sustain the recent pattern of expectation beats while showing that the operating engine, not only adjusted earnings, is strengthening.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The newest quarter held here (Q3 FY2025) was filed Oct 31, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Colgate-Palmolive Company compare with its peers?
Short answer
Colgate-Palmolive Company's score ranks 2nd of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Colgate-Palmolive combines mass-market household staples with a specialized pet-nutrition franchise. Hill's sells everyday food as well as therapeutic diets for health conditions through veterinary clinics, pet retailers and online channels, while the consumer-care portfolio reaches broad retail distribution and dental professionals.
That mix differs from a household-products business dependent solely on supermarket and pharmacy shelves. Pet Nutrition remains the smaller reported segment, yet its veterinary orientation, therapeutic products and dedicated veterinary leadership create a distinct customer and demand structure within the same company.
| Company | Price | Market value | Score |
|---|---|---|---|
| $133.73 Nov 18, 2026 | $4.28B | 96 5-pillar Nov 18, 2026 | |
| Colgate-Palmolive Company (CL) — this page | $98.85 | $78.6B | 93 |
| $64.53 Nov 18, 2026 | $139B | 88 5-pillar Nov 18, 2026 | |
| $170.29 Nov 18, 2026 | $395B | 88 5-pillar Nov 18, 2026 | |
| $113.77 Nov 18, 2026 | $6.73B | 84 5-pillar Nov 18, 2026 | |
| $111.86 Nov 18, 2026 | $26.4B | 82 5-pillar Nov 18, 2026 | |
| $107.24 Nov 18, 2026 | $65.8B | 79 5-pillar Nov 18, 2026 | |
| $118.86 Nov 18, 2026 | $52.1B | 73 5-pillar Nov 18, 2026 | |
| $66.56 Nov 18, 2026 | $84.3B | 72 5-pillar Nov 18, 2026 | |
| $99.69 Nov 18, 2026 | $55.5B | 72 5-pillar Nov 18, 2026 | |
| $69.05 Nov 18, 2026 | $40.8B | 64 5-pillar Nov 18, 2026 | |
| $104.04 Nov 18, 2026 | $37.7B | 64 5-pillar Nov 18, 2026 | |
| $108.39 Nov 18, 2026 | $13.1B | 60 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $95.00 – $112.00
- Consensus target
- $101.30
- Median target
- $102.50
Consensus record · Captured .
Measured against a quoted price of $98.85 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Nov 10, 2026
- Transactions
- 60
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 9
- Other transactions
- 51
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held CL in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported CL in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Colgate-Palmolive Company (CL) — Consumer Defensive
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What makes Hill's Prescription Diet different from Colgate-Palmolive's household brands?
Hill's Prescription Diet consists of therapeutic foods designed to help manage health conditions in dogs and cats. Veterinary clinics form part of its distribution network, giving the franchise a professional animal-health channel that household cleaners and personal-care products do not share.
Is Colgate-Palmolive still mainly an oral, personal and home-care company?
Oral, Personal and Home Care remains the larger reported business. Hill's Pet Nutrition is nevertheless a substantial separate contributor with different products, customers and routes to market.
Why did Colgate-Palmolive's latest sales growth not produce higher operating profit?
Gross profit rose, but selling, general and administrative expense also climbed and operating profit declined. Management is planning heavier advertising support, making the conversion of brand spending into sales and profit an important test.
Can Colgate-Palmolive fund its brands while carrying more debt than cash?
Current cash generation has covered capital spending with ample room remaining, supporting continued business investment. Debt is still far larger than cash, and liquid-asset coverage is not generous, so that capacity depends on operating cash flow remaining durable.
What is the CL stock price today?
The last price recorded for Colgate-Palmolive Company (CL), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the CL price target?
The analyst consensus price target for Colgate-Palmolive Company (CL), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 43 figures on this page — 36 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold CL
Funds in our ETF coverage that list CL among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| FSTA ETF | 2.38% | |
| ProShares - Russell U.S. Dividend Growers ETF (TMDV) | 1.77% | |
| ProShares - S&P 500 Dividend Aristocrats ETF (NOBL) | 1.62% |